Drug interactions between candesartan / hydrochlorothiazide and Viagra
| Results for the following 2 drugs: |
|---|
| candesartan/hydrochlorothiazide |
| Viagra (sildenafil) |
Interactions between your selected drugs
hydrochlorothiazide ↔ sildenafil
Applies to:candesartan/hydrochlorothiazide and Viagra (sildenafil)
Sildenafil can add to the blood pressure-lowering effect of hydrochlorothiazide. Contact your doctor if you experience signs and symptoms of low blood pressure such as dizziness, lightheadedness, fainting, flushing, headache, or a rapid pulse or heart rate. You may be more likely to experience these problems at the beginning of treatment, following a dose increase, or when treatment is restarted after an interruption. Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Switch to professional interaction data
sildenafil ↔ candesartan
Applies to:Viagra (sildenafil) and candesartan/hydrochlorothiazide
Consumer information for this interaction is not currently available.
MONITOR: Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation. When sildenafil 100 mg was coadministered with amlodipine 5 mg or 10 mg to hypertensive patients, the mean additional reduction on supine blood pressure (systolic/diastolic) was 8/7 mmHg. Likewise, in a group of patients whose hypertension was controlled with nifedipine slow-release 30 mg or 60 mg once daily, vardenafil 20 mg produced a mean additional supine blood pressure reduction of 6/5 mmHg compared to placebo. No significant alterations in the pharmacokinetics of nifedipine or vardenafil were observed. When coadministered with amlodipine 5 mg daily or enalapril 20 mg daily, a single 200 mg dose of avanafil produced additional reductions in blood pressure of 3 to 5 mmHg compared to placebo.
MANAGEMENT: Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2013 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
